Emerging Role of ADCs in NSCLC

CE / CME

Fundamentals II: Emerging Role of HER2- and TROP2-Targeted ADCs in NSCLC—What APPs Need to Know

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: November 12, 2024

Expiration: May 11, 2025

Edward B. Garon
Edward B. Garon, MD, MS

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following is NOT a feature of HER2-overexpressing (IHC 3+) NSCLC that could be used to educate patients about their disease?

2.

Rate your confidence in applying current evidence and clinical guidelines in planning individualized therapy using HER2-targeted ADCs in patients with NSCLC?

3.

Which of the following has been the most common AE associated with dato-DXd reported in patients with advanced recurrent NSCLC?

4.

Which of the following is part of the guidelines for the management of grade 1/2 mucositis with datopotamab deruxtecan?